Jounce Therapeutics, Inc. (NASDAQ:JNCE)‘s stock had its “buy” rating reaffirmed by Robert W. Baird in a report released on Friday. They presently have a $30.00 target price on the stock. Robert W. Baird’s target price suggests a potential upside of 103.11% from the company’s current price.

Separately, Zacks Investment Research cut shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $23.67.

Jounce Therapeutics (NASDAQ:JNCE) opened at $14.77 on Friday. Jounce Therapeutics has a 12 month low of $11.05 and a 12 month high of $29.29.

Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. The firm had revenue of $20.29 million during the quarter, compared to analyst estimates of $19.94 million. During the same quarter in the prior year, the firm earned ($7.23) earnings per share. equities research analysts expect that Jounce Therapeutics will post -0.73 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/jounce-therapeutics-jnce-buy-rating-reaffirmed-at-robert-w-baird/1695278.html.

A number of large investors have recently bought and sold shares of JNCE. Acadian Asset Management LLC acquired a new position in Jounce Therapeutics during the second quarter worth $2,359,000. Vanguard Group Inc. raised its position in Jounce Therapeutics by 123.8% during the second quarter. Vanguard Group Inc. now owns 255,060 shares of the company’s stock worth $3,578,000 after acquiring an additional 141,096 shares during the period. JPMorgan Chase & Co. acquired a new position in Jounce Therapeutics during the first quarter worth $2,354,000. Conning Inc. acquired a new position in Jounce Therapeutics during the second quarter worth $1,299,000. Finally, Fosun International Ltd acquired a new position in Jounce Therapeutics during the second quarter worth $1,456,000. Institutional investors own 44.34% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.